论文部分内容阅读
目的探讨第二代子宫内膜去除术诺舒治疗子宫腺肌病月经过多的临床可行性、安全性及疗效。方法回顾性分析29例子宫腺肌病月经过多患者使用诺舒治疗的临床资料。结果 (1)29例患者月经过多平均病程(23±5.58)个月(13~69个月)。均顺利进行诺舒手术,诺舒主机工作时间为68~158 s,平均(98.00±17.50)s,无手术并发症;(2)29例患者中,术后6、12、18个月有效率分别为89.6%、82.7%和75.8%,闭经率分别为82.7%、82.7%和68.9%,痛经缓解率分别为75.8%、68.9%和68.9%;术前25例合并贫血,平均血红蛋白[(75.80±15.69)g/L]与术后6个月[(86.67±16.34)g/L]比较,差异有统计学意义(P<0.01);(3)术前宫腔<5 cm组与≥5 cm组有效率和闭经率比较,差异均有统计学意义(P<0.05)。子宫腔≥5 cm组术后4例因症状反复并加重行子宫全切除术。结论诺舒可有效治疗子宫腺肌病月经过多,但疗效可能受子宫体腔长度影响,需要进一步研究。
Objective To investigate the clinical feasibility, safety and curative effect of second-generation endometrial ablation Nose Shu for the treatment of menopausal adenomyosis. Methods A retrospective analysis of 29 cases of adenomyosis over-menopausal patients treated with nosok clinical data. Results (1) The mean duration of menorrhagia in 29 patients was (23 ± 5.58) months (13-69 months). All had Nosocom smooth operation. The working hours of Nosocom were 68 ~ 158 s, with an average of (98.00 ± 17.50) s, no complications. (2) Among the 29 patients, 6,12,18 months after operation The rates of dysmenorrhea were 75.8%, 68.9% and 68.9%, respectively. Preoperative 25 patients with anemia, mean hemoglobin [(75.80% ± 15.69) g / L] and 6 months after operation ([86.67 ± 16.34] g / L], the difference was statistically significant (P <0.01); (3) cm group and amenorrhea rate, the difference was statistically significant (P <0.05). In the uterine cavity ≥5 cm group, 4 cases underwent repeated hysterectomy due to repeated symptoms. Conclusion Noroxam effective treatment of adenomyosis menorrhagia, but the effect may be affected by the body cavity length, need further study.